Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…
Biotechnology
US, South San Francisco [HQ]
Lobbying Analysis
Lobbying · US Senate · Influence
Tempest Therapeutics, Inc. has no lobbying expenses in our database.
History
Download| FY | Quarter | Expense For Lobby Disclosure | LDA Reference |
|---|---|---|---|
| No data |